

Phone: 855.696.7254 Fax: 855.329.6725 www.ForwardScience.com info@ForwardScience.com



Park Cities Periodontics & Implant Dentistry is now performing Enhanced Oral Cancer Screenings

~ Dr. Tomlin is using OralID™ Fluorescence Technology as an adjunct to her oral cancer screening. ~

Park Cities Periodontics & Implant Dentistry joined forces with Forward Science, the manufacturer of OralID[™], and became a member of the ID for Life[™] Program to promote early detection and public awareness of oral cancer in the office. Dr. Tomlin will be offering enhanced oral cancer screenings during scheduled appointments to new and current patients.

Oral Cancer is not a rare disease and unfortunately it is on the rise. This year, approximately 51,540 will be diagnosed with oral cancer in the United States alone. Due to late stage discovery one American dies every hour from oral cancer.

Dr. Tomlin uses an oral cancer screening device, OralID, in efforts to discover oral cancers in their earliest stages. Currently, up to 70% of oral cancers are found in late stages (stage III, IV), resulting in a 5-year survival rate of less than 50%. OralID has the ability to "highlight" these abnormalities in much earlier stages, before it is actually visible to your dental professional, in turn increasing the 5-year survival rate up to 80-90%.

About Forward Science


Forward Science is a privately held biotechnology company based in Houston, Texas. OralID, Forward Science's flagship product, is an award-winning oral cancer screening device that allows clinicians to discover abnormalities that may not be seen under traditional white light examinations. Forward Science quickly expanded its product portfolio in efforts to provide clinicians with a complete program to battle the rising trends of oral cancer. With the launch of the ID for LifeTM Program, Forward Science has evolved into the industry leader for oral oncology. The ID for LifeTM Program includes the following in an effort to change the trends for oral cancer: screening device (OralID), diagnostic tests (CytID, PathID, hpvID, phID), and treatment options (SalivaMAX).

OralID[®] CytID[®] hpvID[®]

S FORWARD

PathID

^D phID[®] SalivaMAX[®] SalivaCAINE[®]



HPV is the cause of the fastest growing oral cancer population under the age of 45 and is responsible for a 15x increase in oral cancer diagnosis.

- 40% of new diagnosis are YOUNG, NON-SMOKERS
- 45,750 new cases of oral cancer of the oral cavity & pharynx
- 57% 5-year survival rate for oral cancers
- 69% of oral cancers are found in LATE STAGE
- 8,650 deaths due to late diagnosis

FORWARD

- 1 out of 2 men will develop cancer in their lifetime
- 1 out of 3 women will develop cancer in their lifetime
- Men are 2x more likely to develop general oral cancers
- HPV related cancers are 6-7 time more common in men than women
- Those with 6 or more oral sex partners are 8.6x more likely than those who have never had oral sex

• Number of oral cancers has increased over a 7 year period, where all other cancers have declined

• HPV is transmitted through saliva, sexual and skin-to-skin contact

FORWARD phID SalivaMAX SalivaCAINE